Back to top

Image: Bigstock

Hologic Inc.

Read MoreHide Full Article

 Hologic delivered an outstanding performance in the second quarter of fiscal 2015, squarely beating the Zacks Consensus Estimate. The company delivered strong organic revenue and earnings growth across the board in the reported quarter and expects further improvement in its financials going forward, as validated by its raised guidance for fiscal 2015. Also, global Novasure sales, which had been declining over the past few quarters, improved in the reported quarter at CER. Currently, the company's strategy lies in strengthening its R&D pipelines and constantly enhancing its operational efficiencies in the near term. However, Hologic continues to face tough competition, particularly in the tomosynthesis market.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Hologic, Inc. (HOLX) - free report >>

Published in